VILIP3 overexpression in HCC patients was correlated with poor survival, and more importantly, knockdown of VILIP3 was found to inhibit cell proliferation and motility, suggesting that VILIP3 may be a useful biomarker and therapeutic target in HCC. The gene discussed is HPCAL1; the disease is hepatocellular carcinoma.